ARTICLE | Deals
J&J picks Emergent as manufacturing partner in $1B COVID-19 vaccine initiative
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 24, 2020 1:15 AM UTC
Updated on Apr 24, 2020 at 5:58 PM UTC
Emergent will be the U.S. manufacturing partner for Johnson & Johnson to support the pharma's commitment to produce 1 billion doses of a COVID-19 vaccine.
Emergent BioSolutions Inc. (NYSE:EBS), which said the deal is valued at $135 million, will deploy its CDMO services and reserve manufacturing capacity beginning this year to prepare for commercial manufacturing of the adenovirus-based COVID-19 vaccine planned for 2021. The partners are negotiating a long-term deal to support large-scale manufacturing in 2021...